Janssen Search
Search results
Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
Feb 26, 2024 United States IMBRUVICA ® is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, providing additional flexibility for patients who may have difficulty swallowing tablets or capsules HORSHAM, PA ...
IDV Newsroom
Welcome to the Janssen Infectious Diseases & Vaccines Virtual Newsroom Janssen’s Commitment to Combating Infectious Diseases A Message from Penny Heaton and James Merson At Janssen, we have a strong legacy of daring to deliver medicines and vaccines ...
Chronic Infections
Article Type: Infectious Diseases & Vaccines Chronic Infections HIV The global HIV epidemic began more than 40 years ago. There's been significant progress in tackling this virus since then, but HIV remains one of the most significant ...
Improving Outcomes for Patients with Prostate Cancer with Early Intensive Treatment
Improving Outcomes for Patients with Prostate Cancer with Early Intensive Treatment Despite tremendous progress in our understanding of prostate cancer and significant expansion in the therapeutic landscape, prostate cancer continues to represent the ...
New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Jun 26, 2023 United States 92 percent of pregnancies treated with nipocalimab resulted in a live birth, with 54 percent delivering at or after 32 weeks without intrauterine transfusions 1 SPRING HOUSE, PENNSYLVANIA, JUNE 26, 2023 – The Janssen ...
Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
Apr 06, 2023 United States HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U ...
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
Dec 11, 2023 United States Oral presentations at the 2023 ASH Annual Meeting include patient-reported outcomes from the CARTITUDE-4 study and longer-term efficacy and safety data from CARTITUDE-2 study cohorts A and B, show the promise of CARVYKTI ® in ...
Story – Cork Lower Harbour Energy Group
Cork Lower Harbour Energy Group In 2008 Janssen began collaborating with DePuy Synthes, GlaxoSmithKline (GSK) and Novartis to form the Cork Lower Harbour Energy Group (CLHEG), a unique industry collaboration focused on developing a green solution to ...
Emmanuelle Quilès
EMMANUELLE QUILÈS WORLDWIDE VICE PRESIDENT CARDIOVASCULAR, METABOLISM AND PULMONARY HYPERTENSION JANSSEN GLOBAL COMMERCIAL STRATEGY ORGANIZATION (GCSO) Emmanuelle Quilès is Worldwide Vice President, Cardiovascular, Metabolism and Pulmonary Hypertension. ...
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
May 30, 2023 United States This is the first and only single tablet combination therapy application to be submitted for review in the U.S. for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all ...